Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Baird Remains Bullish Following Cempra's (CEMP) 4Q; Focus Remains on Solithromycin Launch
February 25, 2016 7:09 AM ESTBaird maintained an Outperform rating on Cempra, Inc. (NASDAQ: CEMP), and cut the price target to $33.00 (from $38.00), following the company's 4Q. Cempra is currently focused on completing regulatory submissions for Solithromycin in CABP and prepping for launch in 2017. As such, the company's 4Q results are... More
Cempra (CEMP) Tops Q4 EPS by 11c
February 24, 2016 4:26 PM ESTCempra (NASDAQ: CEMP) reported Q4 EPS of ($0.48), $0.11 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.79 million versus the consensus estimate of $3.89 million.
For earnings history and earnings-related data on Cempra (CEMP) click here.
... More